A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours

November 27, 2016 updated by: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase I Trial to Investigate Safety and Tolerability Profile and Pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours

To investigate safety, tolerability and pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours that are not eligible for conventional or intensive treatment. The dose of HS-10241 will be escalated to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of HS-10241 in advanced cancer patients. At the same time, pharmacokinetic characteristics and preliminary efficacy of HS-10241 will be observed in advanced cancer patients. To determine the recommended dosage regimen for phase II.

Study Overview

Status

Unknown

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Beijing
      • Beijing, Beijing, China, 100021
        • Recruiting
        • Cancer Hospital Chinese Academy of Medical Sciences
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 63 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Histologically confirmed advanced or metastatic solid tumor for which standard therapy does not exist, has failed, or has been refused.
  2. c-MET positive patients preferred in dose escalation phase; c-MET of patients must fulfill ICH++~+++ or FISH≥4 times in dose expansion phase.
  3. Confirmed that there are at least 1 can be measured in accordance with the standard RECIST1.1 by CT or MRI.
  4. 18 ~65 years of age.
  5. ECOG performance status of 0~1.
  6. Life expectancy of at least 3 months.
  7. Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less (except alopecia).
  8. Acceptable hematologic status (without hematologic supports including hematopoietic factor, blood transfusion) defined below:

    • Absolute neutrophil count (ANC) ≥ 1500/μL
    • Platelet count ≥ 100000/μL
    • Hemoglobin ≥ 9.0 g/dL
  9. Acceptable liver function defined below:

    • Total bilirubin ≤ 2 times upper limit of normal range (ULN)
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times ULN; however, ≤ 5 times ULN in a subject who has liver metastases
  10. Acceptable renal function defined below:

    • Serum creatinine ≤ 1.5 times ULN or calculated creatinine clearance (by the Cockcroft-Gault formula) ≥ 60 mL/minutes
  11. Acceptable coagulation status defined below:

    • Prothrombin time < 1.5 times ULN
    • Partial thrombin time < 1.5 times UL
  12. HIV Ag/Ab(-).
  13. HCV Ab(-);or HCV Ab(+) but HCV RNA(-).
  14. HBsAg(-)and HBcAb(-)in dose escalation phase;HBV DNA<1×103copies/ml if HBsAg(+)or HBcAb(+)in dose expansion phase.
  15. Ability to understand the purposes and risks of the trial and his/her informed consent using the human research ethics committee (HREC) approved informed consent form was obtained before the entering the trial.

Exclusion Criteria:

  1. Treatment with other c-MET TKI( specific target or multi-target);
  2. Anti-cancer treatment with radiation therapy(not including non target lesions receiving palliative radiotherapy), chemotherapy,hormonotherapy or surgery(small surgery, including the implantation of external equipment or fine needle aspiration, at least 7 days; diagnostic or palliative surgery, at least 14 days) within 4 weeks (6 weeks for nitrosoureas or Mitomycin C)prior to trial entry.
  3. Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product
  4. Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular disease.
  5. Symptomatic brain metastases or unstable brain metastases (notes: Patients with asymptomatic brain metastases previously treated for the study, but must be kept stable for at least 4 weeks and receive a stable dose of the drug)
  6. Obvious neurological and mental disorder.
  7. Other previous or concomitant tumors (except for the effective treatment of melanoma, cervical carcinoma in situ, ductal carcinoma in situ or malignant tumor after effective treatment, remission 3 years and considered to have been cured).
  8. Active, uncontrolled bacterial, fungal infections, requiring systemic therapy.
  9. Recent venous thrombosis (including deep vein thrombosis or pulmonary embolism within 0.5 year of trial entry)
  10. History of organ allograft, autologous stem cell transplantation, or allogeneic stem cell transplantation.
  11. Participation in an investigational drug or device trial within 4 weeks prior to the trial entry.
  12. Anti-cancer treatment with radiation therapy, chemotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or Mitomycin C) prior to trial entry.
  13. Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery
  14. Taking a medication that is a moderate or strong inhibitor or inducer of CYP2C9; taking a medication that prolongs QT interval and has a risk of Torsades de Pointes .
  15. Pregnant (positive serum beta human chorionic gonadotropin [β-HCG] test at Screening) or is currently breast-feeding, their partner anticipates becoming pregnant/impregnating during the trial or within 6 months after receiving the last dose of trial treatment.
  16. Known drug abuse or alcohol abuse.
  17. Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HS-10241 100mg
HS-10241 100mg daily
Experimental: HS-10241 200mg
HS-10241 200mg daily
Experimental: HS-10241 400mg
HS-10241 400mg daily
Experimental: HS-10241 600mg
HS-10241 600mg daily
Experimental: HS-10241 800mg
HS-10241 800mg daily
Experimental: HS-10241 1000mg
HS-10241 1000mg daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
MTD of HS-10241 based on the incidence of dose limiting toxicities
Time Frame: 4 weeks
4 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Elimination half-life(T1/2) of HS-10241
Time Frame: 4 weeks
4 weeks
Progression-free survival (PFS)
Time Frame: 12 months
12 months
Max concentration (Cmax) of HS-10241
Time Frame: 4 weeks
4 weeks
Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
Time Frame: 8 weeks
8 weeks
Incidence and intensity of Adverse Events according to Common Toxicity Criteria for AEs (CTCAE version 4.0)
Time Frame: 8 weeks
8 weeks
Area under the plasma concentration versus time curve (AUC) of HS-10241
Time Frame: 4 weeks
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2016

Primary Completion (Anticipated)

November 1, 2018

Study Completion (Anticipated)

November 1, 2021

Study Registration Dates

First Submitted

November 11, 2016

First Submitted That Met QC Criteria

November 27, 2016

First Posted (Estimate)

November 30, 2016

Study Record Updates

Last Update Posted (Estimate)

November 30, 2016

Last Update Submitted That Met QC Criteria

November 27, 2016

Last Verified

November 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HS-10241-101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carcinoma

Clinical Trials on HS-10241

Subscribe